Draft:International Myeloma Working Group

Study of SAC's Role in Multiple Myeloma and Erythropoietin-Induced Osteoporosis

Retrieved on: 
Wednesday, June 10, 2020
RTT, Anatomy, Organ systems, Multiple myeloma, Osteoporosis, Bone, Tumors of the hematopoietic and lymphoid tissues, Draft:International Myeloma Working Group

"While we have had amazing recovery cases of patients with multiple myeloma undergoing SAC therapy, the collaborative research will help us to gain a deeper understanding of the healing pathways of SAC for multiple myeloma and erythropoietin-induced osteoporosis."

Key Points: 
  • "While we have had amazing recovery cases of patients with multiple myeloma undergoing SAC therapy, the collaborative research will help us to gain a deeper understanding of the healing pathways of SAC for multiple myeloma and erythropoietin-induced osteoporosis."
  • Multiple myeloma is the second most common hematological malignancy.
  • Multiple myeloma is highly associated with bone destruction, where osteoclasts are more active than osteoblasts.
  • This two-year collaborative research focuses on pharmacokinetics study of SAC, biological safety of SAC, and in vivo effects of SAC in multiple myeloma and erythropoietin-induced osteoporosis.

International Myeloma Foundation Partners with Medscape Oncology to Create Professional Education Series on Continuous Treatment in Multiple Myeloma

Retrieved on: 
Thursday, January 9, 2020
International Myeloma Foundation, Non-profit organizations based in California, Myeloma Foundation, Multiple myeloma, Health, Draft:Brian Durie, United States, Draft:International Myeloma Working Group

LOS ANGELES, Jan. 9, 2020 /PRNewswire/ --The International Myeloma Foundation announces the launch of a new program created in partnership with Medscape Oncology that offers healthcare professionals an opportunity to earn continuing medical education (CME) credit. "

Key Points: 
  • LOS ANGELES, Jan. 9, 2020 /PRNewswire/ --The International Myeloma Foundation announces the launch of a new program created in partnership with Medscape Oncology that offers healthcare professionals an opportunity to earn continuing medical education (CME) credit. "
  • Everything You Need to Know About Continuous Treatment in Multiple Myeloma " is a series of online educational courses for hematology/oncology specialists, nurses, and pharmacists.
  • Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest foundation focusing specifically on multiple myeloma.
  • In 2012, the IMF launched the Black Swan Research Initiative, a groundbreaking research project aimed at curing myeloma.

International Myeloma Foundation Presents Research, Video Reports, Social Media Coverage at 2019 American Society of Hematology Meeting (ASH)

Retrieved on: 
Wednesday, December 4, 2019
Medical specialties, Health, Medicine, International Myeloma Foundation, Non-profit organizations based in California, Multiple myeloma, Norwalk, Connecticut, Myeloma Foundation, Myeloma protein, Multiple Myeloma Research Foundation, Draft:International Myeloma Working Group, Draft:Brian Durie

Here, 18 MRD-negative patients were found to be positive using Qip to detect low levels of myeloma protein.

Key Points: 
  • Here, 18 MRD-negative patients were found to be positive using Qip to detect low levels of myeloma protein.
  • It shows that T cells that react against myeloma cells have a pattern that is negative for the antigen CD27.
  • International Myeloma Working Group (IMWG) Breakfast Meeting, Dec. 7: The 200-plus members of the IMWG , the IMF's research division, collaborate on a broad range of myeloma research projects.
  • Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest foundation focusing specifically on multiple myeloma.

Study finds racial disparities in treatment of multiple myeloma patients

Retrieved on: 
Thursday, October 17, 2019
RTT, Multiple myeloma, Plasma cell dyscrasias, Draft:International Myeloma Working Group

WASHINGTON, Oct. 17, 2019 /PRNewswire/ -- Among patients with multiple myeloma, African Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances.

Key Points: 
  • WASHINGTON, Oct. 17, 2019 /PRNewswire/ -- Among patients with multiple myeloma, African Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances.
  • The time between diagnosis and treatment is crucial to multiple myeloma outcomes.
  • If treatment is delayed, multiple myeloma patients can suffer organ damage, kidney dysfunction, anemia, skeletal fractures, infections, and other serious conditions.
  • The use of these therapies has more than doubled survival of multiple myeloma patients within the past decade.

Study in JNCCN Supports Idea that Higher Patient Volumes are Associated with Longer Survival in Multiple Myeloma

Retrieved on: 
Tuesday, September 17, 2019
Multiple myeloma, RTT, Health, Norwalk, Connecticut, Orphan drugs, Draft:International Myeloma Working Group, Medicine, Monoclonal antibodies, Draft:The PROMISE Study

"Multiple myeloma care is complicated and nuanced, with many specific treatments and management scenarios," said senior researcher William A.

Key Points: 
  • "Multiple myeloma care is complicated and nuanced, with many specific treatments and management scenarios," said senior researcher William A.
  • "Our results show that provider experience, and potentially access to resources at a comprehensive cancer center, may improve survival in patients with multiple myeloma.
  • Or, it might be that patients who are seen by higher volume providers are more likely to have other unmeasured or confounding factors associated with better survival.
  • In this scenario, the current study reiterates the importance of clinical experience in the management of multiple myeloma patients.

Multiple Myeloma Research Foundation (MMRF) Expands Leadership Team to Accelerate Precision Medicine and Cures

Retrieved on: 
Tuesday, September 10, 2019
Research, Clinical trials, Philanthropy, Health, Foundation, Science, Oncology, Norwalk, Connecticut, Multiple Myeloma Research Consortium, Health, Multiple Myeloma Research Foundation, Medical specialties, Multiple myeloma, International Myeloma Foundation, Draft:International Myeloma Working Group

The Multiple Myeloma Research Foundation (MMRF) announced today that Hearn Jay Cho, MD, PhD, will serve as the organizations Chief Medical Officer (CMO).

Key Points: 
  • The Multiple Myeloma Research Foundation (MMRF) announced today that Hearn Jay Cho, MD, PhD, will serve as the organizations Chief Medical Officer (CMO).
  • At the MMRF, he will also lead the Multiple Myeloma Research Consortium (MMRC), a group of 25 leading research centers dedicated to researching and advancing treatment options for multiple myeloma patients.
  • A pioneer in precision medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for all multiple myeloma patients by relentlessly pursuing innovations that accelerate the development of precision treatments for cancer.
  • The Multiple Myeloma Research Consortium (MMRC) is a 509 (a) (3) non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma.

The American Journal of Managed Care® Launches ‘A Review of the Treatment for Multiple Myeloma’

Retrieved on: 
Tuesday, July 30, 2019
Health, Other Health, Oncology, Other Science, Other Communications, Research, Managed care, Hospitals, Communications, Science, Multiple myeloma, RTT, The American Journal of Managed Care, Draft:International Myeloma Working Group, Smouldering myeloma

The American Journal of Managed Care (AJMC), the leading multimedia peer-reviewed journal dedicated to issues in managed care, presents its most recent Peer Exchange panel discussion, A Review of the Treatment for Multiple Myeloma.

Key Points: 
  • The American Journal of Managed Care (AJMC), the leading multimedia peer-reviewed journal dedicated to issues in managed care, presents its most recent Peer Exchange panel discussion, A Review of the Treatment for Multiple Myeloma.
  • The video series features several experts in the field of multiple myeloma who will review the current treatment landscape for multiple myeloma.
  • Mary E. DeRome, MSc, director of medical communications and education at Multiple Myeloma Research Foundation.
  • Other titles in theAJMCfamily includeThe American Journal of Accountable Care and two evidence-based series,Evidence-Based Oncology andEvidence-Based Diabetes Management.

Multiple Myeloma Research Foundation (MMRF) Presents Research Abstracts During 2019 ASCO Annual Meeting

Retrieved on: 
Monday, June 3, 2019
Health, Social media, Philanthropy, Communications, Marketing, Research, Public relations, Investor relations, Science, Foundation, Fund Raising, General Health, Norwalk, Connecticut, Multiple Myeloma Research Consortium, Health, Multiple Myeloma Research Foundation, Multiple myeloma, Medical specialties, International Myeloma Foundation, Draft:International Myeloma Working Group

Today, the Multiple Myeloma Research Foundation (MMRF) announced three research abstracts to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting & Exposition inChicago, IL.

Key Points: 
  • Today, the Multiple Myeloma Research Foundation (MMRF) announced three research abstracts to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting & Exposition inChicago, IL.
  • The abstracts focus on the Multiple Myeloma Research Consortium MyDRUG Master Protocol, electronic medical record (EHR) data collection for a new MMRF myeloma patient registry, and examination of patient knowledge gaps surrounding optimizing their decision-making and outcomes.
  • A pioneer in precision medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for multiple myeloma by relentlessly pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients.
  • The Multiple Myeloma Research Consortium (MMRC) is a 509 (a) (3) non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma.

The International Myeloma Foundation to Honor Cancer Researchers Meletios A. Dimopoulos, MD, and María-Victoria Mateos, MD, on June 11 in Amsterdam

Retrieved on: 
Thursday, May 23, 2019
International Myeloma Foundation, Non-profit organizations based in California, Health, Norwalk, Connecticut, Multiple myeloma, Myeloma Foundation, States of the United States, Multiple Myeloma Research Foundation, Draft:International Myeloma Working Group, Myeloma Canada

Durie Outstanding Achievement Award to Mara-Victoria Mateos, MD during the 2019 International Myeloma Working Group Summit, June 10-12.

Key Points: 
  • Durie Outstanding Achievement Award to Mara-Victoria Mateos, MD during the 2019 International Myeloma Working Group Summit, June 10-12.
  • More than 100 international blood cancer experts will gather at the Summit in Amsterdam to collaborate on new multiple myeloma treatment guidelines and ongoing research projects leading to a cure for this blood cancer.
  • Durie Outstanding Achievement Award:Named for the IMF Chairman, the award is given to an individual who has demonstrated excellence in multiple myeloma research.
  • Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest foundation focusing specifically on multiple myeloma.

OncoTracker Expands Multiple Myeloma Intellectual Property

Retrieved on: 
Tuesday, March 12, 2019
Multiple myeloma, RTT, B-cell maturation antigen, Medical specialties, Branches of biology, Medicine, Hematology, Draft:International Myeloma Working Group, Smouldering myeloma

WEST HOLLYWOOD, Calif., March 12, 2019 /PRNewswire/ -- OncoTracker, Inc. announced that it has strengthened its intellectual property portfolio in multiple myeloma by completing an agreement with the Institute for Myeloma and Bone Cancer Research to acquire worldwide rights to its intellectual property regarding both diagnostic testing and a new therapeutic approach for treating these patients.

Key Points: 
  • WEST HOLLYWOOD, Calif., March 12, 2019 /PRNewswire/ -- OncoTracker, Inc. announced that it has strengthened its intellectual property portfolio in multiple myeloma by completing an agreement with the Institute for Myeloma and Bone Cancer Research to acquire worldwide rights to its intellectual property regarding both diagnostic testing and a new therapeutic approach for treating these patients.
  • This patent claims methods of assaying for BCMA (B-cell maturation antigen) in serum or other biological samples from patients with multiple myeloma.
  • OncoTracker has years of experience accurately measuring soluble BCMA in the blood of thousands of multiple myeloma patients.
  • OncoTracker further possesses intellectual property related to two multiple myeloma therapies in clinical trials.